spacer U.S. Department of Health and Human Services U.S. Department of Health and Human Services www.hhs.gov U.S. Department of Health and Human Services spacer
spacer
spacer
National Institutes of Health
spacer
spacer
NIH Research Portfolio Online Reporting Tools (Report) Report, Data and Analyses of NIH Research Activities
spacer
spacer
NIH Recovery Act Investment Reports
spacer
spacer
 
spacer
<< BACK
spacer
spacer
ARRA Investments in Diabetes and Cardiovascular Disease


Public Health Burden
Cardiovascular disease (CVD) is the leading cause of death for people with diabetes.  Adults with diabetes are at least twice as likely to die of heart disease or to have a stroke than people without diabetes.

Prediction
Researchers are working to understand factors that contribute to the development and progression of CVD in people with diabetes.  Seizing opportunities offered by established, large-scale clinical and epidemiological studies, a variety of ARRA funded grants are exploring ways to improve CVD prediction:
  • A project is using information from a clinical trial in people with type 2 diabetes and heart disease to examine the association between fat cell hormones and CVD, including their potential usefulness in prognosis, monitoring effects of therapy, and identifying risk.1
  • Little is known about the development and progression of preclinical CVD in young people with type 1 diabetes.  A grant will use an ongoing study of diabetes in youth to assess presence of, and risk factors for, sub-clinical CVD in adolescents and young adults with type 1 diabetes.2
  • A project will use data and samples from a long-term (20 years +), well-characterized cohort of people with type 1 diabetes to identify biomarkers for progression of CVD and other diabetes complications, and to determine if they provide insight into how blood glucose control strategies reduce risk of complications.3
  • A project will use two large cohorts of diabetes patients to study multiple, potentially interrelated mechanisms of vascular damage that could reveal another set of biomarkers for CVD and result in better predictive and therapeutic strategies.4
Intervention
Research has helped to improve knowledge of, and options for, managing CVD in people with diabetes.  Still, new or improved therapeutic strategies to help prevent onset of CVD, minimize its progression, or simply treat disease symptoms are needed.  ARRA grants are supporting a variety of studies of innovative approaches to manage CVD in people with diabetes:
  • A project will try to develop biodegradable, microscopic particles (“nanoparticles”) to specifically target impaired vascular cells and deliver agents that can repair function and provide future protection from disease-induced damage.5
  • Studying the role of diet in modifying CVD risk factors, a project will test the ability of a specific dietary component, digestion-resistant starch, to improve metabolic biomarkers of CVD risk in individuals already showing a predisposition to develop type 2 diabetes.6
Population-Specific Research
Some ethnic and racial populations in the U.S. have disproportionately high rates of type 2 diabetes and CVD.  Moreover, type 2 diabetes and CVD are becoming significant global health challenges, particularly in the developing world.  ARRA funded grants are supporting studies aimed at understanding population-specific risk factors and improving outcomes:
  • A project will conduct a large, systematic study of clinical, epidemiological, biochemical, and genetic factors linking type 2 diabetes to heart disease in South Asians (Pakistan).7
  • CVD is the leading cause of death in American Indian/Alaska Native populations, with diabetes as the leading risk factor for CVD.  A project will study viability and sustainability of an intervention designed to improve diet and exercise and decrease diabetes and CVD risk in two urban American Indian populations.8
  • A project will capitalize on a multi-center community health study to assess socioeconomic, sociocultural, and psychosocial factors contributing to CVD and metabolic syndrome prevalence in a large, diverse group of Hispanics from four regions across the U.S.9



  1. 1R01HL087214-01A2 -- Adipokines and Cardiovascular Disease in Diabetes -- Somers, Virend K (MN)
  2. 1R01DK078542-01A2 -- Sub Clinical Cardiovascular Disease In Youth (SEARCH CVD) -- Dabelea, Dana (CO)
  3. 1R01DK080732-01A1 -- Biomarkers For Complications In Type 1 Diabetes (DCCT/EDIC) -- Hazen, Stanley L (OH)
  4. 1R01DK080043-01A2 -- Lipoproteins And PEDF In The Vascular Complications Of Diabetes -- Lyons, Timothy J (OK)
  5. 1R21HL093689-01A1 -- Treating Endothelial Dysfunction With Targeted Nanoparticle-Based BH4 Delivery -- Meininger, Cynthia J (TX)
  6. 1RC1DK086472-01 -- Effects of Resistant Starch on Lipid and Glucose Metabolism in Insulin Resistance -- Bergeron, Nathalie; Krauss, Ronald M (CA)
  7. 1RC1TW008485-01 -- Markers of the Metabolic Syndrome Linking Type 2 Diabetes and MI in South Asia -- Danesh, John Navid;Rader, Daniel James;Saleheen, Danish (PA)
  8. 1RC2MD004738-01 -- Addressing Diabetes/CVD Health Disparities Among American Indians: A Transdisciplinary Approach-- Beals, Janette L ;Moore, Kelly Roberta; (CO)
  9. 1RC2HL101649-01 -- Ancillary To HCHS/SOL: Sociocultural Factors And CVD Risk/Prevalence In Hispanics -- Gallo, Linda C ;Penedo, Frank J (CA)


spacer
 
spacer
spacer
Homespacer| Investment Reportsspacer| spacerFAQsspacer| spacerContact Usspacer| spacerRePORT Home

Office of Extramural Research spacer spacer spacer spacer spacer USA.gov logo spacer spacer

Page Last Updated on June 30, 2018 NIH...Turning Discovery Into Health®